Zharp1-211

Zharp1-211 is a RIPK1 kinase inhibitor with an EC50 of 53 nM and a Kd of 8.7 nM. Zharp1-211 reduces IFN-γ-induced STAT1 activation. Zharp1-211 can be used in the research of graft-versus-host disease and colon cancer[1].

Product Specifications

CAS Number

[2258671-41-7]

UNSPSC

12352005

Target

RIP kinase; STAT

Type

Reference compound

Related Pathways

Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/zharp1-211.html

Purity

99.15

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(OC1CCOCC1)N2C3=CC(C(C=C4)=CN5C4=NC(NC(C6CC6)=O)=C5)=CN=C3CC2

Molecular Formula

C24H25N5O4

Molecular Weight

447.49

References & Citations

[1]Yu X, et al. A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis. Blood. 2023 Mar 2;141 (9) :1070-1086.